NASDAQ:IMNN Imunon (IMNN) Stock Price, News & Analysis $1.07 +0.03 (+2.88%) (As of 09/9/2024 ET) Add Compare Share Share Today's Range$1.02▼$1.1050-Day Range$0.96▼$3.3252-Week Range$0.48▼$3.65Volume160,306 shsAverage Volume1.18 million shsMarket Capitalization$64.25 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Imunon alerts: Email Address Imunon MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,208.4% Upside$14.00 Price TargetShort InterestHealthy2.83% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$24,500 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.71) to ($0.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.60 out of 5 starsMedical Sector409th out of 899 stocksPharmaceutical Preparations Industry186th out of 420 stocks 3.5 Analyst's Opinion Consensus RatingImunon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageImunon has only been the subject of 1 research reports in the past 90 days.Read more about Imunon's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.83% of the float of Imunon has been sold short.Short Interest Ratio / Days to CoverImunon has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Imunon has recently decreased by 85.79%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldImunon does not currently pay a dividend.Dividend GrowthImunon does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMNN. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Imunon this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for IMNN on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Imunon to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Imunon insiders have bought more of their company's stock than they have sold. Specifically, they have bought $24,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Imunon is held by insiders.Percentage Held by InstitutionsOnly 4.47% of the stock of Imunon is held by institutions.Read more about Imunon's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Imunon are expected to grow in the coming year, from ($1.71) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Imunon is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Imunon is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImunon has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Imunon's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingExposed: The Plot to Destroy AmericaIs Your Family Prepared for Kamala’s America? The coup has already begun. Kamala Harris is just one step away from the presidency, and her plan will devastate every state in America. Find out how to shield your wealth and thrive in the coming chaos.Get the inside scoop and learn how to protect your savings. About Imunon Stock (NASDAQ:IMNN)Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.Read More IMNN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMNN Stock News HeadlinesAugust 17, 2024 | insidertrades.comInsider Buying: Imunon, Inc. (NASDAQ:IMNN) CEO Buys 25,000 Shares of StockSeptember 9 at 4:06 PM | globenewswire.comUPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive ManagementSeptember 10, 2024 | Banyan Hill Publishing (Ad)Kamala’s Secret 3-Word Plan to Destroy America… Are You Prepared?America’s Slow Decline into Hell As Kamala Harris rises to power, her 3-word agenda threatens every American’s freedom and financial security.August 28, 2024 | globenewswire.comIMUNON to Host R&D Day on September 18thAugust 15, 2024 | msn.comIMNN: Positive Results for OVATION 2 Trial Supports Advancing IMNN-001 Into Phase 3 Study…August 14, 2024 | globenewswire.comIMUNON Reports Second Quarter 2024 Financial Results and Provides a Business UpdateAugust 7, 2024 | globenewswire.comIMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024August 4, 2024 | lse.co.ukImunon Share Price (IMNN.US)September 10, 2024 | Banyan Hill Publishing (Ad)Kamala’s Secret 3-Word Plan to Destroy America… Are You Prepared?America’s Slow Decline into Hell As Kamala Harris rises to power, her 3-word agenda threatens every American’s freedom and financial security.July 31, 2024 | msn.comWhy Imunon (IMNN) Stock Is Down 60% TodayJuly 31, 2024 | finance.yahoo.comImunon’s shares soar after IL-12 therapy success in Phase II trialJuly 31, 2024 | finance.yahoo.comIMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesJuly 31, 2024 | marketwatch.comImunon Shares More Than Double on Ovarian Cancer Study ResultsJuly 31, 2024 | benzinga.comImunon (NASDAQ:IMNN) Stock Quotes, Forecast and News SummaryJuly 31, 2024 | msn.comNano-Cap IMUNON's Lead Candidate Shows Overall Survival Of Around 11 Months In Untreated Ovarian Cancer PatientsJuly 30, 2024 | finanznachrichten.deImunon, Inc.: IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001July 30, 2024 | benzinga.comDow Jumps 200 Points; Pfizer Earnings Top ViewsJuly 30, 2024 | marketwatch.comImunon's Advanced Ovarian Cancer Study Data Shows Survival ImprovementSee More Headlines Receive IMNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/10/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMNN CUSIPN/A CIK749647 Webwww.imunon.com Phone(609) 896-9100Fax609-896-2200Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$14.00 Low Stock Price Target$14.00 Potential Upside/Downside+1,208.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-165.52% Return on Assets-102.47% Debt Debt-to-Equity RatioN/A Current Ratio1.51 Quick Ratio1.51 Sales & Book Value Annual Sales$500,000.00 Price / Sales128.51 Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book0.75Miscellaneous Outstanding Shares60,050,000Free Float8,931,000Market Cap$64.25 million OptionableNot Optionable Beta2.13 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Michael H. Tardugno (Age 73)Executive Chairman Dr. Khursheed Anwer M.B.A. (Age 64)Ph.D., Executive VP & Chief Scientific Officer Comp: $632.26kMr. Timothy J. Tumminello CPA (Age 66)Chief Accounting Officer & Controller Comp: $108.31kDr. Sebastien Hazard M.D. (Age 52)Executive VP & Chief Medical Officer Key CompetitorsAcasti PharmaNASDAQ:ACSTKezar Life SciencesNASDAQ:KZRLakeshore BiopharmaNASDAQ:LSBYS BiopharmaNASDAQ:YSNextCureNASDAQ:NXTCView All CompetitorsInsidersStacy LindborgBought 25,000 shares on 8/15/2024Total: $24,500.00 ($0.98/share)View All Insider Transactions IMNN Stock Analysis - Frequently Asked Questions How have IMNN shares performed this year? Imunon's stock was trading at $0.68 at the start of the year. Since then, IMNN stock has increased by 57.4% and is now trading at $1.07. View the best growth stocks for 2024 here. How were Imunon's earnings last quarter? Imunon, Inc. (NASDAQ:IMNN) released its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.04. How do I buy shares of Imunon? Shares of IMNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMNN) was last updated on 9/10/2024 by MarketBeat.com Staff From Our PartnersYour Crypto Future is at StakeWhat if I told you that bananas could make you a millionaire? No, this isn't a joke – I'm talking about the...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredKamala’s Secret 3-Word Plan to Destroy America… Are You Prepared?America’s Slow Decline into Hell As Kamala Harris rises to power, her 3-word agenda threatens every America...Banyan Hill Publishing | SponsoredWarning For Nvidia HoldersHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart mi...Stansberry Research | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredMike Huckabee Puts His Faith in This to Protect His RetirementMike Huckabee's Urgent Warning: Safeguard Your Financial Future NowAmerican Hartford Gold Group | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
